ZEO ScientifiX Announces That Unaudited Monthly Sales Surpassed $1.0 million in April 2026, the First Time The Company Has Achieved This Milestone.

Rhea-AI Summary

ZEO ScientifiX (OTCQB:ZEOX) reported that unaudited monthly sales surpassed $1.0 million in April 2026, the first time it has reached this level. Management views this as a key growth inflection, driven by a newly built internal sales force and physician education masterclass programs supporting regenerative medicine clinics.

Positive

• First $1.0M+ sales month achieved in April 2026 (unaudited)
• New dedicated internal sales force supporting physician-run clinic adoption
• Ongoing regenerative medicine masterclass programs to educate and support physicians

Negative

• None.

News Market Reaction – ZEOX

+6.44%

+6.44% Session close to close

In the May 12 session, ZEOX gained 6.44%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT LAUDERDALE, FL / ACCESS Newswire / May 12, 2026 / ZEO ScientifiX (OTCQB:ZEOX) ("ZEO" or the "Company"), a regenerative medicine products company serving physician-run clinics across the United States, today announced that it had reached a defining commercial milestone. For the first time in Company history, ZEO's single month unaudited sales surpassed the $1 million mark in April 2026. Management believes that this achievement marks a significant inflection point in ZEO's growth trajectory and reflects the successful execution of a physician-first commercial strategy that we believe is uniquely positioned to scale.

At the core of this momentum is the Company's newly implemented dedicated internal sales force. Building on this foundation, ZEO is actively looking to add additional full-time sales professionals to accelerate physician onboarding, broaden geographic reach, and deepen penetration within existing clinic networks. As ZEO scales its sales infrastructure, management expects physician count, revenue per account, and total Company revenue to grow in parallel.

Another significant driver of this momentum has been ZEO's physician education strategy, including its ongoing regenerative medicine masterclass programs. These initiatives are designed to educate physicians and physician practices on the clinical, operational, and practice-development aspects of regenerative medicine. Management believes this physician-first education model has helped accelerate adoption, deepen trust with clinical partners, and support more sustainable account growth

Management Commentary

Ian Bothwell, Chief Executive Officer of ZEO ScientifiX, said, "April's results represent a genuine inflection point for ZEO. Physicians across the country are actively seeking high-quality, differentiated solutions in the rapidly evolving market for regenerative medicine therapeutics, and our Company is meeting that demand at scale. The growth we are reporting we believe is not incidental. It reflects a deliberate build, and we are accelerating it."

He added, "Our expanding sales force and our physician education initiatives are operating in parallel. We are not simply moving product. We are educating physicians, supporting practices, and helping clinicians build sustainable, high-performing regenerative medicine programs. That educational infrastructure, including our masterclass model, is a major reason this growth is beginning to compound."

Sean Vega-Stanton, M.S., General Manager of ZEO ScientifiX, said, "Breaking through $1 million in a single month is not just a number. It is proof of concept. We continue to pursue strategies to expand our physician network, and we believe the next phase of growth will be larger than what we have already achieved. The infrastructure is in place. The market is ready. We are moving."

About ZEO ScientifiX (OTCQB:ZEOX)

ZEO ScientifiX is a regenerative medicine products company dedicated to advancing patient outcomes through physician-run clinics. ZEO supplies cutting-edge biologics and regenerative therapies, partnering with clinicians to drive clinical excellence and sustainable practice growth.

Forward-Looking Statements

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

Media Contact:

ZEO ScientifiX, Inc.
Karlista Maroney
Director of Growth Strategy
IR@zeoscientifix.com

SOURCE: Zeo ScientifiX, Inc.

View the original press release on ACCESS Newswire

FAQ

What sales milestone did ZEO ScientifiX (OTCQB:ZEOX) reach in April 2026?

ZEO ScientifiX reported unaudited monthly sales surpassing $1.0 million in April 2026, its first time above this level. According to ZEO ScientifiX, management considers this a defining commercial milestone and a key indicator of its current growth trajectory.

Why does the April 2026 $1 million sales milestone matter for ZEOX shareholders?

The April 2026 sales above $1.0 million mark ZEO ScientifiX’s first single month at this level. According to ZEO ScientifiX, management believes this represents an inflection point tied to its physician-first strategy and expanding commercial infrastructure.

How is ZEO ScientifiX growing its sales force to support future revenue growth?

ZEO ScientifiX has implemented a dedicated internal sales force and plans to add more full-time sales professionals. According to the company, these hires aim to accelerate physician onboarding, expand geographic reach, and deepen penetration in existing regenerative medicine clinic networks.

What role do physician education programs play in ZEO ScientifiX’s growth strategy (ZEOX)?

Physician education, including regenerative medicine masterclass programs, is a core growth driver for ZEO ScientifiX. According to the company, these programs support clinical, operational, and practice-development training, helping build trust, increase adoption, and support more sustainable account growth.

How does ZEO ScientifiX describe the impact of its April 2026 results on future growth?

ZEO ScientifiX management views April 2026 as a genuine growth inflection point, not a one-off result. According to ZEO ScientifiX, existing infrastructure and market demand position the company to pursue a larger next phase of growth.

What is ZEO ScientifiX’s commercial focus in the regenerative medicine market?

ZEO ScientifiX focuses on delivering regenerative medicine products to physician-run clinics across the United States. According to the company, a physician-first commercial strategy and educational support aim to help practices build sustainable, high-performing regenerative medicine programs.